Gynecologic Cancers: Clinical Research Progress of Resection

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1109

Special Issue Editor


E-Mail Website
Guest Editor
School of Public Health, Center of Postgraduate Medical Education, 01-809 Warsaw, Poland
Interests: pelvic exenteration; gynecological surgery; operative morbidity; gynecological malignancy; palliative indications; curative intent
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Both primary cancer nests and cancer relapse nests localized in the pelvis can be removed using the en bloc resection technique. Indeed, a recent analysis shows the mortality rate following pelvic exenteration to be somewhere between 0.7% and 6.4% when an acceptable level of exenteration is achieved.

Unsurprisingly, extensive surgery of this kind requires support at the organization level. While just such an organizing trend has been observed in renowned oncological centers, it needs to be more widely promoted and connected with the centralization of patients in referring hospitals. The success of the plan is more closely related to the surgical skill of the team, as achieving R0 resection (which is the only type of surgery with a curative intent) requires considerable surgical experience. Even pelvic exenteration due to palliative indications may prolong overall patient survival and have reliable functional results when R0 resection is achieved. Moreover, should the primary intent of the surgery change from palliative to curative, patient benefit will likely increase if a well-trained multidisciplinary team performs the procedure. Such a team not only understands pelvic anatomy but also has the knowledge and surgical skills to be able to imagine the sequelae of the resection procedure and to perform reconstructive procedures later. In summary, knowledge and information need to be widely disseminated. The resulting discussions will increase awareness among gynecological oncologists and so help to promote training programs aimed at expanding the surgical skills of qualified physicians.

Prof. Dr. Lukasz Wicherek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 1131 KiB  
Review
The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
by Klaudia Żak, Małgorzata Satora, Ilona Skrabalak, Rafał Tarkowski, Marta Ostrowska-Leśko and Marcin Bobiński
Cancers 2024, 16(5), 1063; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16051063 - 05 Mar 2024
Viewed by 785
Abstract
There were high hopes for the new antiangiogenic medicament, bevacizumab, which could inhibit the creation of new blood vessels through binding to isoform A of vascular endothelial growth factor (VEGF). However, it is not only blood vessels that are responsible for tumor cell [...] Read more.
There were high hopes for the new antiangiogenic medicament, bevacizumab, which could inhibit the creation of new blood vessels through binding to isoform A of vascular endothelial growth factor (VEGF). However, it is not only blood vessels that are responsible for tumor cell spread. During the process of tumor growth, lymphangiogenesis is mediated by other members of the VEGF family, specifically VEGF-C and VEGF-D, which act independent to bevacizumab. Therefore, based on the mechanism of bevacizumab action and the processes of angio- and lymphangiogenesis, we formed three hypotheses: (1) if the lymph nodes in primary ovarian cancers are metastatic, the outcome of bevacizumab treatment is worsened; (2) concerning the second-line treatment, bevacizumab will act in a weakened manner if recurrence occurs in lymph nodes as opposed to a local recurrence; (3) patients treated by bevacizumab are more likely to have recurrences in lymph nodes. These hypotheses raise the issue of the existing knowledge gap, which concerns the effect of bevacizumab on metastatic lymph nodes. Full article
(This article belongs to the Special Issue Gynecologic Cancers: Clinical Research Progress of Resection)
Show Figures

Figure 1

Back to TopTop